Alpha-Synuclein / SNCA (A30P Mutant) Human Protein

CAT#: SA6000X

Alpha-Synuclein / SNCA (A30P Mutant) human recombinant protein, 0.5 mg

Product Images

Specifications

Product Data

• Species: Human
• Expression Host: E. coli
• Expression cDNA Clone or AA Sequence: MDVFMKGLSK AKEGVVAAAE KTKQGVAEAP GKTKEGVLYV GSKTKEGVVH GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA
• Predicted MW: 14.486 kDa
• Concentration: lot specific
• Purity: >95% by SDS-PAGE
• Buffer: Presentation State: Purified
  State: Liquid protein
  Buffer System: 20 mM Tris-HCl buffer (pH 7.5) containing 0.1 M NaCl
• Preparation: Liquid protein
• Protein Description: A Parkinson's disease-related point mutant (A30P) of alpha-synuclein. A30P mutant of alpha-synuclein was overexpressed in E. coli and the recombinant protein was purified to apparent homogeneity by taking advantage of the thermosolubility of the protein and by using conventional column chromatography techniques.
• Storage: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C. Avoid repeated freezing and thawing.
• Stability: Shelf life: one year from despatch.

Reference Data

• RefSeq: NP_000336
• Locus ID: 6622
• Cytogenetics: 4q22.1
• Synonyms: NACP; PARK1; PARK4; PD1
• Summary: 'Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Alternatively spliced transcripts encoding different isoforms have been identified for this gene. [provided by RefSeq, Feb 2016]'
• Protein Families: Druggable Genome
• Protein Pathways: Alzheimer's disease, Parkinson's disease